All Online

1 - 3 of 3 results

Refine

Active filters

Peripheral Arterial Disease
1.5 CME CREDITS

Until the advent of the COMPASS trial, secondary prevention in patients with peripheral artery disease consisted of either aspirin or clopidogrel monotherapy. A new era is emerging in which, by adding low-dose DOACs to low-dose aspirin, medical therapy may reduce the need for major vascular surgery or endovascular procedures. In this Virtual Expert Roundtable, the faculty will discuss the latest evidence, indications, and guideline-based utilization of dual antiplatelet therapy.


1 CME CREDIT

Faculty will review the prior data regarding antiplatelet and anticoagulant therapy. He will also present highlights from the recent late breaking clinical trial presentations from the European Society of Cardiology.


1 CME CREDIT

Until the advent of the COMPASS trial, secondary prevention in patients with peripheral artery disease consisted of either aspirin or clopidogrel monotherapy. A new era is emerging in which, by adding low-dose DOACs to low-dose aspirin, medical therapy may reduce the need for major vascular surgery or endovascular procedures. In this Video Webcast, the faculty will discuss the latest evidence, indications, and guideline-based utilization of dual antiplatelet therapy. In addition to an in-depth look at PAD therapy, participants in this session will receive insights on the latest in secondary prevention options for ESUS and a review of proper dosing for long-term anticoagulation to prevent recurrent events in patients with venous thromboembolic disease.